Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Sangamo Therapeutics, Inc.
Type
Public
Industry Biomedicine
Founder Edward O. Lanphier II
Headquarters Richmond, California, USA
Number of employees
84
Website http://www.sangamo.com

Sangamo BioSciences (NASDAQ: SGMO) is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene.

Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

Investment goal date:
Dividends reinvested
Sangamo Therapeutics, Inc. SGMO report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-01
--
--
Q4 2017
2018-02-28
--
--
Q4 2017
2018-02-16
--
--
Q3 2017
2017-11-09
-0.1500
0.0000
Q2 2017
2017-08-09
-0.1700
-0.1700
Q1 2017
2017-05-10
-0.2300
-0.2300
Q4 2016
2017-02-28
-0.1400
-0.1400
Q3 2016
2016-10-26
-0.2700
-0.2700
Q2 2016
2016-08-03
-0.3800
-0.3800
Q1 2016
2016-05-02
-0.2300
-0.2300
Q4 2015
2016-02-09
-0.2000
-0.2000
Q3 2015
2015-10-28
-0.1300
-0.1300
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ADAGE CAPITAL PARTNERS GP LLC
3000000
BAKER BROS. ADVISORS LP
4530901
BlackRock Fund Advisors
3215835
BlackRock Inc.
5618851
BlackRock Institutional Trust Company, N.A.
1847789
DEERFIELD MANAGEMENT CO
837963
FIC CAPITAL INC
940909
FMR LLC
1611083
GEODE CAPITAL MANAGEMENT, LLC
633964
GRANAHAN INVESTMENT MANAGEMENT INC/MA
1032859
NORTHERN TRUST CORP
903176
ROYCE & ASSOCIATES LLC
751100
STATE STREET CORP
1231989
Vanguard Group, Inc
3087650
WASATCH ADVISORS INC
7060135
Major Shareholders
Name Relationship
Total Shares
Holding stocks
ANDO DALE G
0.1600% (107328)
SGMO /
NICHOL GEOFFREY
0.2300% (159676)
SGMO /
LANPHIER EDWARD O II
1.7200% (1175094)
SGMO /
LARSON JOHN WILLIAM
0.3100% (214660)
SGMO / WAGE /
Wolff Henry Ward
0.3000% (206829)
ABIO / CALA / PTLA / SGMO /
Mento Steven J
0.0200% (12270)
CNAT / SGMO /
Gregory Philip D
0.1700% (116410)
BLUE / SGMO /
RA CAPITAL MANAGEMENT, LLC
5.4000% (3683000)
% ()